News | October 27, 2025
Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Medico Remedies receives order worth US$ 1,781,000
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
BIL also holds an option to increase its equity stake by an additional 15%
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Subscribe To Our Newsletter & Stay Updated
